Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475330 · ClinicalTrials.gov registry record · Phase 2
Dietary Flaxseed in NSCLC
A Phase 2 study, sponsored by Abramson Cancer Center at Penn Medicine.
- Terminated
- Registry status
- Phase 2
- Development phase
- 33
- Enrollment target
NCT02475330 is a Phase 2 study that was terminated before completion, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 33 participants.
The verdict
NCT02475330, a Phase 2 study, was terminated before completion, sponsored by Abramson Cancer Center at Penn Medicine.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 33 participants
- Enrollment target
Study Summary
This single arm Phase II trial will investigate the feasibility of dietary flaxseed (FS) supplementation in subjects receiving definitive chemoradiotherapy for non-small cell lung cancer (NSCLC). Subjects will ingest FS for a period of approximately 8 to 9 weeks during the course of radiation treatment. Study participation and surveillance will last approximately 6 months. Subject specimen collection will include: blood, urine, and buccal swabs at 5 time points.
Interventions
- DIETARY_SUPPLEMENT Flaxseed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2015-05 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02475330
The ClinicalTrials.gov registry entry for NCT02475330 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 33 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Flaxseed is the first listed.
NCT02475330 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02475330 about?
NCT02475330 is a clinical study titled "Dietary Flaxseed in NSCLC". This single arm Phase II trial will investigate the feasibility of dietary flaxseed (FS) supplementation in subjects receiving definitive chemoradiotherapy for non-small cell lung cancer (NSCLC). Subjects will ingest FS for a period of approximately 8 to 9 weeks during the course of radiation treatm...
What is the current status of trial NCT02475330?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 33 participants. The study started on 2015-05. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02475330?
The interventions under investigation include: Flaxseed (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02475330?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.